Open AccessEnhancement of 1,25-Dihydroxyvitamin D3-Mediated Antitumor Activity With Dexamethasone
Author(s) -
Wei-bong Yu,
Mariann C. McElwain,
Ruth A. Modzelewski,
Derick M. Russell,
David C. Smith,
Donald L. Trump,
Candace S. Johnson
Publication year - 1998
Publication title -
jnci journal of the national cancer institute
Language(s) - English
Resource type - Journals
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/90.2.134
Subject(s) - dexamethasone , in vivo , clonogenic assay , calcitriol receptor , endocrinology , medicine , receptor , chemistry , in vitro , biology , pharmacology , biochemistry , microbiology and biotechnology
The active metabolite of vitamin D, i.e., 1,25-dihydroxycholecalciferol (1,25-D3), inhibits the growth of murine SCCVII/SF squamous cell carcinoma cells, both in vitro and in vivo. However, in vivo use of 1,25-D3 is hampered as a result of hypercalcemia (i.e., elevated levels of calcium in the blood). Glucocorticoids, such as dexamethasone, affect calcium absorption and modulate vitamin D receptor binding and have been used to treat hypercalcemia. In this study, we examined the effect of dexamethasone on tumor growth inhibition by 1,25-D3.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom